Hexarelin sits at the least selective end of the growth hormone secretagogue class in the published record: it releases growth hormone forcefully through the ghrelin receptor GHS-R1a, and it carries ACTH-driven cortisol and a modest prolactin rise along with it. That spillover is a recognized characteristic of the earlier growth hormone releasing peptides and the reason more selective compounds such as ipamorelin were later developed. Hexarelin holds no FDA approval, and the human hormonal data come from small clinical and pharmacology studies rather than large regulated trials, so its full endocrine footprint is documented in outline rather than in detail.
Hexarelin acts at the ghrelin receptor GHS-R1a and releases growth hormone alongside ACTH-driven cortisol and a modest prolactin rise, an off-target pattern shared with GHRP-6 and GHRP-2 that prompted the development of the more selective secretagogue ipamorelin, and it is not FDA-approved.
The cortisol rise is a receptor-distribution effect, not a contaminant or a dosing accident. GHS-R1a, the receptor Hexarelin binds, is not confined to the growth-hormone-producing somatotrophs; it is also expressed in hypothalamic regions and on cells linked to the stress axis, so ghrelin-like signaling reaches the corticotroph as well. Research indicates the ACTH response is not purely a local pituitary event, with corticotropin-releasing hormone and especially arginine vasopressin implicated as hypothalamic intermediaries in how GHRP-type peptides drive that cell.
Hexarelin's cortisol rise follows ACTH release driven by GHS-R1a activation outside the somatotrophs, with CRH and arginine vasopressin implicated as hypothalamic intermediaries, and human studies place it alongside the growth hormone pulse rather than long after it.
Set against the growth hormone pulse the same dose produces, Hexarelin's prolactin effect is real but comparatively minor: the record describes a modest, short-lived bump in circulating prolactin, usually less prominent than the cortisol response and framed as a side signal rather than a primary action. Precise, reproducible numbers are the missing piece, since the human data come from small pharmacology studies of an unapproved peptide.
| Criteria | Prolactin | Growth hormone |
|---|---|---|
| Cell source | Lactotrophs, secondarily activated | Somatotrophs, directly targeted |
| Magnitude | Modest, measurable bump | Pronounced pulse at the same dose |
| Duration | Transient, returns toward baseline | Acute pulse, the intended action |
| Standing in the record | Side signal, smaller than cortisol | Primary and best-documented effect |
| Data quality | No reproducible average figure published | Consistently reported across GHRP studies |
Hexarelin raises circulating prolactin modestly and transiently through secondary lactotroph activation, an effect smaller than both its growth hormone pulse and its cortisol response, and the small pharmacology studies available do not supply a reproducible average figure for the size of the increase.
Selectivity is the axis this comparison runs on, and Hexarelin sits at the unselective end of it. The older GHRPs, Hexarelin, GHRP-6, and GHRP-2, all raise ACTH, cortisol, and prolactin alongside growth hormone, and ipamorelin and the GHRH analogs are the named contrasts precisely because they do not. None of the peptides named here holds FDA approval as a marketed product, so the ranking describes research findings rather than a menu of approved options.
Hexarelin, GHRP-6, and GHRP-2 reliably raise ACTH, cortisol, and prolactin alongside growth hormone, ipamorelin was specifically selected to release growth hormone at the same receptor with little to no meaningful cortisol or prolactin rise, and GHRH analogs such as sermorelin avoid the spillover by acting through a separate receptor.
The assumption that tolerance fades evenly across every hormone is where this part of the profile gets misread. Hexarelin's growth hormone releasing effect is well documented as prone to partial desensitization with continued or frequent administration, thought to reflect downregulation and reduced sensitivity at GHS-R1a, but whether the ACTH, cortisol, and prolactin responses attenuate on the same schedule is not cleanly established.
Hexarelin's growth hormone response partially desensitizes with continued or frequent administration through downregulation at GHS-R1a, while research on GHRP peptides indicates the ACTH, cortisol, and prolactin responses can follow a separate time course, and the human evidence for this unapproved peptide does not support predicting any individual's pattern.
Dose is the largest single lever on how much cortisol and prolactin signal Hexarelin produces, and the two curves do not run parallel. The off-target hormonal effects reported for GHRP-type peptides are dose-related, becoming more pronounced as the amount administered rises, while the growth hormone response tends to reach a plateau beyond which additional peptide yields little extra growth hormone. Past that plateau the extra dose buys mostly stress-axis and prolactin activity, which is where the ratio of intended to unintended effect turns against the compound.
The cortisol and prolactin responses to Hexarelin are dose-related and reported to keep climbing with dose, while the growth hormone response tends to plateau, so dosing past that plateau buys mostly off-target stress-axis and prolactin activity rather than additional growth hormone.
The concern is not the single dose; it is what these hormones do when they run high over time. Persistently elevated cortisol is associated with impaired glucose regulation, increased abdominal fat deposition, suppressed immune function, loss of muscle and bone, and disrupted sleep and mood, which is why a repeated cortisol stimulus reads as an unwanted feature rather than a benign one. Hexarelin is an unapproved research peptide with limited long-term human safety data, so the risk picture is genuinely uncertain rather than reassuringly small.
Repeated Hexarelin exposure carries a recurring cortisol stimulus associated with impaired glucose regulation, abdominal fat deposition, immune suppression, muscle and bone loss, and disrupted sleep and mood, alongside a modest prolactin elevation linked to reproductive hormone disruption and reduced libido, and no long-term human safety data exist for this unapproved research peptide.
Beyond growth hormone, ACTH, cortisol, and prolactin, the pituitary's remaining output lines stay comparatively quiet, and the record is candid about why. Evidence for a meaningful Hexarelin effect on thyroid-stimulating hormone and the thyroid hormones it governs is thin, and the compound is not characterized as a reliable thyroid stimulator; its influence on the gonadotropins, luteinizing hormone and follicle-stimulating hormone, is neither prominent nor consistent in the literature. The explanation offered is cell-population susceptibility: the corticotrophs and lactotrophs cross-activate from ghrelin receptor signaling more readily than the thyrotrophs and gonadotrophs do.
| Criteria | Cortisol and prolactin axes | Thyroid and gonadotropin axes |
|---|---|---|
| Pituitary cells | Corticotrophs and lactotrophs | Thyrotrophs and gonadotrophs |
| Cross-activation from GHS-R1a | Readily susceptible | Comparatively resistant |
| Signal in the literature | Clear and repeatable | Thin and inconsistent |
| Evidence level | Small human pharmacology studies | Limited study, no reliable effect characterized |
Hexarelin's documented endocrine footprint centers on growth hormone, ACTH, cortisol, and prolactin, with no reliable thyroid or gonadotropin effect characterized in the literature, and the limited human dataset for this unapproved peptide means the quiet on those axes reflects both a genuinely smaller effect and a thin body of study.
Educational use only. This article describes what the published scientific and clinical literature reports about Hexarelin. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
